Arm Everywhere — March 24, 2026 event + AGI CPU merchant silicon launch incl. China push + IBM collab + SoftBank pivot (top catalyst)
Key Questions
What is the main announcement from Arm's March 24, 2026 event?
Arm launched the Neoverse V3 136-core 3nm AGI CPU designed for agentic AI, with production slated for H2 by partners like Meta, OpenAI, and TSMC. This marks a shift to merchant silicon, including sales in China despite licensing restrictions.
What revenue projections are associated with the AGI CPU launch?
The AGI CPU is projected to generate $1B in revenue for FY28 and $15-25B by FY31. These figures highlight its potential impact on Arm's growth in the AI sector.
How has Arm's stock performed recently?
Arm's stock is at $143.86 following a Morgan Stanley Equal Weight downgrade with a $150 PT, after a 67.6% YTD surge. Despite the dip, it has seen strong gains driven by AI optimism.
What are the analyst price targets and ratings for Arm?
Price targets range from $150 to $240, with an average of $175 and a Moderate Buy consensus. Valuations are split, with DCF fair value at $72 versus $148 bull case.
What collaborations were highlighted in the event?
Arm announced an IBM collaboration for z16 and Granite platforms in 2027, alongside a SoftBank pivot. Hyperscalers are expected to be 90% Arm-based by 2029.
Why did Arm's stock slide recently?
The stock dropped after Morgan Stanley's downgrade to Equal Weight at $150, citing valuation concerns amid hype. It gapped down 6.75-8% on the news, despite prior surges.
Is Arm planning sales in China despite restrictions?
Yes, Arm plans to sell AGI CPUs in China despite core licensing bans, leveraging merchant silicon. This expands its market reach in agentic AI.
What makes Arm a 'credible AI play' according to analysts?
Arm's move from IP blueprints to actual AGI CPU silicon positions it strongly in AI, with upgrades noting its role in CPU bottlenecks for agentic AI. Management sees the stock as underpriced given the opportunity.
Neoverse V3 136-core 3nm AGI CPU launched for agentic AI (Meta/OpenAI/TSMC H2 prod, China sales despite licensing ban, $1B FY28/$15-25B FY31 rev); stock $143.86 post-MS EW $150 downgrade/67.6% YTD surge/valuation split ($72 DCF fair vs $148 bull); PTs $150-240 avg $175 Moderate Buy; IBM z16/Granite 2027; hyperscalers 90% Arm '29.